BioCentury
ARTICLE | Company News

Santhera musculoskeletal news

September 5, 2016 7:00 AM UTC

Santhera received a $246,000 grant from FDA under its Orphan Products Grants Program to support the ongoing open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating omigapil in ambulatory a...